Clinical Trials Logo

Clinical Trial Summary

Although patients with locally advanced rectal cancer and resectable liver/pulmonary metastasis could benefit from surgery resection, these patients still have a poorer prognosis compared to those without distal metastasis. Based on previous studies, there is no confirmation of whether these patients could benefit from preoperative immunotherapy combined with conventional chemoradiotherapy. This study proposes a combination therapy, preoperative short-course radiotherapy followed by neoadjuvant chemotherapy and anti-PD-1 immunotherapy, for microsatellite-stable patients with locally advanced rectal cancer and resectable liver/pulmonary metastasis, to assess its impact on tumor retreat, decline of postoperative metastasis and recurrence, and the disease-free survival and overall survival of patients. Besides, this study will provide high-level medical evidence for future clinical treatment of patients with advanced rectal cancer.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05359393
Study type Interventional
Source Fudan University
Contact Xinxiang Li, MD
Phone 86-21-64175590
Email lxx1449@163.com
Status Not yet recruiting
Phase Phase 2
Start date December 1, 2022
Completion date September 1, 2027

See also
  Status Clinical Trial Phase
Not yet recruiting NCT05524155 - Sintilimab Combined With Regorafenib and HAIC in Patients With Colorectal Liver Metastasis Phase 2
Recruiting NCT02632201 - Immunotherapy Using Pluripotent Killer-Human Epidermal Growth Factor Receptor-2 (PIK-HER2) Cells for the Treatment of Advanced Gastric Cancer With Liver Metastasis Phase 1/Phase 2
Enrolling by invitation NCT01715402 - Optimization of Health Expenditure in Liver Surgery N/A
Recruiting NCT01035385 - Compare FOFLOX4 in Preoperative and Postoperative and Postoperative in Resectable Liver Metastasis Colorectal Cancer (MCC) Phase 3
Recruiting NCT05098847 - Cryoablation Combined With Sintilimab Plus Lenvatinib In Previously Treated Unresectable Liver Metastasis From Solid Tumors Phase 2
Withdrawn NCT02651090 - Evaluation of Suspected Liver Pathology in Patients With Contraindications for Contrast Enhanced CT and/or MRI Phase 3
Withdrawn NCT01775280 - Response of Hepatic Tumors to Radioembolization Phase 2
Completed NCT00068068 - Photodynamic Therapy With Talaporfin Sodium (LS11) in Treating Patients With Refractory Colorectal Liver Metastases Phase 2
Terminated NCT02453490 - Compare Efficacy and Safety of Raltitrexed-based and 5fu-based Neoadjuvant Chemotherapy for Colorectal Liver Metastasis Phase 3
Recruiting NCT04622423 - Advanced Therapies for Liver Metastases
Completed NCT00892424 - Sorafenib-RT Treatment for Liver Metastasis (SLIM) Phase 1/Phase 2
Completed NCT00028405 - Photodynamic Therapy System for Patients With Refractory/Unresponsive Solid Tumors Phase 1
Completed NCT03801915 - Perioperative MVT-5873, a Fully Human Monoclonal Antibody Against a CA 19-9 Epitope, for Operable CA 19-9 Producing Pancreatic Cancers, Cholangiocarcinomas, and Metastatic Colorectal Cancers Phase 2
Completed NCT02218801 - A Prospective Colorectal Liver Metastasis Database With an Integrated Quality Assurance Program
Completed NCT01834014 - Exploratory Study in Achievement of Improved Survival by Molecular Targeted Chemotherapy and Liver Resection for Not Optimally Resectable Colorectal Liver Metastases N/A
Completed NCT00083785 - Study of the Litx™ System Combined With Chemotherapy in Patients With Colorectal Liver Metastases Phase 2
Active, not recruiting NCT03428477 - EPA for Metastasis Trial 2 Phase 3
Completed NCT02316028 - Phase I:Decitabine by Hepatic Arterial Infusion(HAI) in Unresectable Liver Metastases Colorectal Cancer (CRC) Phase 1/Phase 2
Completed NCT01785212 - The Influence of Two Different Hepatectomy Methods on Transection Speed and Chemokine Release From the Liver N/A
Completed NCT03785210 - Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic Cancers Phase 2